An analysis on Vical’s Allovectin-7 technology and potential outcome

An analysis on Vical’s Allovectin-7 technology and potential outcome

(As originally published on Seeking Alpha on Mar 22, 2011).

Vical’s stock price has rallied the last few weeks. At the time of this writing the company has a market cap of roughly $180M and a price per share of $2.50. At the end of 2010, total cash was $60M after raising $37M in Sept 2010 in a stock offering that cut the stock price almost by half. It is worth pointing out that at the time of the offering, Vical had less than $15M cash. According to the recently published annual report, Vical burned $28.2M in 2010 and it expects to burn between $22M and $27M in 2011.

[Read more...]

Delcath

Delcath

(As originally published on Oct 22 2010 on Seeking Alpha)

Methods related to isolating a specific organ of the body in order to deliver a large amount of chemotherapy have been developed over  the last 40 years. These are, among others, Hepatic Arterial Infusional therapy (HAI) and Isolated Hepatic Perfusion (IHP). Main drugs administered have been doxorubicin, melphalan, TNF, oxaliplatin, 5-FU and some others to treat aggressive malignancies such as colorectal cancer, hepatocellular carcinoma, breast cancer, sarcoma and a number of methastases from primary cancers. [Read more...]